HR 6466, the Forced Abortion Prevention and Accountability Act, prohibits non-consensual administration of abortion drugs (like mifepristone or misoprostol) to pregnant women without their informed consent. It criminalizes this act with penalties up to 25 years in prison and allows victims to sue for triple damages, psychological/physical injury compensation, and attorney fees. The bill directly affects pregnant women who might face coerced procedures and medical providers or others who administer such drugs without consent. Key provisions include criminal penalties for the act itself, enhanced penalties for serious injury or death, and a civil remedy framework for victims seeking compensation.
The Freedom to Heal Act of 2025 creates a new federal registration process for physicians to directly administer Schedule I investigational drugs under the "Right to Try" framework. It requires physicians to apply to the Attorney General with evidence of state compliance, manufacturer agreements, and training, and limits the amount of drugs they may possess based on approved applications. The bill mandates the Attorney General to issue interim rules within 240 days and final rules within two years covering drug delivery, storage, recordkeeping, and registration management. This affects physicians treating eligible patients with Schedule I drugs under federal Right to Try provisions, not the patients themselves.
HR 6423, the HELP Copays Act, requires health insurance plans and coverage to count financial assistance from non-profits or drug manufacturers toward patient cost-sharing limits like deductibles and copayments. This directly affects patients enrolled in health insurance who receive such assistance for prescription drugs, ensuring the help they get reduces their out-of-pocket costs faster. The bill amends key health laws to mandate that these payments are included when calculating whether a patient has met their deductible or copayment threshold. The change applies to all prescription drugs, including specialty drugs and those subject to prior authorization, but does not alter how insurers manage drug access through tools like step therapy. It takes effect for plan years starting in 2026.
This bill increases the tax exclusion for capital gains when selling a primary residence. It doubles the exclusion amount from $250,000 (for single filers) to $500,000 and from $500,000 (for married couples) to $1,000,000. The bill also adds an inflation adjustment for amounts after 2025, tying future increases to the cost-of-living adjustment. It directly affects homeowners who sell their primary residence and would otherwise owe tax on profits exceeding the previous limits. The changes apply to sales after the bill's enactment date.
The Rx ACCESS Act improves prescription drug access for TRICARE beneficiaries, including military service members, retirees, and their families, by establishing fair reimbursement standards for pharmacies and expanding medication choice. It requires pharmacies to be reimbursed at actual drug costs (or the national average drug cost for certain medications) plus a standard dispensing fee, while banning hidden fees like point-of-sale charges. Starting October 1, 2026, beneficiaries can choose how they receive non-generic medications for ongoing health conditions. The law also mandates annual audits to verify reimbursement fairness and ensure pharmacy networks provide accessible care, especially in rural and underserved areas.
HR 6372, the D.C. Shield Law Repeal Act, repeals the Human Rights Sanctuary Amendment Act of 2022 (D.C. Law 24-257), which had modified District of Columbia protections for certain immigrant residents. The bill restores the previous legal framework that existed before the 2022 amendment took effect. This directly affects D.C. law and its implementation regarding immigrant rights within the District.
This bill establishes a new interagency Task Force to dismantle foreign scam operations targeting Americans, particularly through "pig butchering" scams in Southeast Asia. The Task Force, chaired by the Secretary of State, will coordinate efforts across multiple agencies to shut down scam centers, impose sanctions on perpetrators, and support victims of trafficking. It requires a detailed strategy within 180 days and annual reports to Congress on progress, including sanctions imposed and funds recovered. The bill authorizes $30 million for these efforts in fiscal years 2026-2027, focusing on countries like Cambodia, Laos, and Burma where scam centers operate with forced labor.
This bill would amend the Anti-Terrorism Act of 1987 to designate the Muslim Brotherhood as a terrorist organization and prohibit its operations within the United States. It would require the President to designate the Muslim Brotherhood as a foreign terrorist organization under immigration law and impose new visa restrictions, including immediate revocation of current visas, for individuals identified as members. The bill mandates annual reports from the Secretary of State identifying Muslim Brotherhood branches worldwide and determining which should be designated as terrorist organizations under existing laws. These provisions would directly affect Muslim Brotherhood members, branches, and affiliated organizations seeking entry to or operating within the United States.
This bill creates a new IRS procedure allowing victims of domestic violence or abuse to seek relief from joint tax liability on past returns. It requires the IRS to presume that a spouse who knew about tax errors on a joint return but didn't challenge them did so due to fear or duress from the abusive partner. Survivors requesting relief can provide evidence of abuse without disclosing details in IRS notices to the non-requesting spouse, protecting their privacy. The bill directly affects survivors who filed joint tax returns with abusive partners and were unaware of tax errors or unable to challenge them due to abuse.
This bill suspends payment limits for agricultural subsidies for the 2025 crop year, removing caps on payments to farmers. It also establishes a new option for farmers to receive 50% of their expected 2025 crop payments as an advance by December 1, 2025, if they opt in. The remaining balance is paid later after the marketing year ends, with farmers required to repay any overpayment if the final amount exceeds the advance. The bill directly affects farmers growing covered commodities (like corn, soybeans) who choose to participate in the advance payment program.
HR 4431, the Improving Capital Allocation for Newcomers Act of 2025, changes rules for certain venture capital funds under the Investment Company Act of 1940. It raises the maximum number of investors allowed from 250 to 2,000 and increases the asset threshold from $10 million to $150 million for funds seeking an exemption. This directly affects venture capital funds that want to operate under the 3(c)(1) exemption, allowing them to pool capital from more investors and manage larger funds without full SEC registration. The bill makes these specific numerical adjustments to the existing exemption rules.
Give Kids a Chance Act of 2025 This bill expands the Food and Drug Administration’s (FDA’s) authority with respect to research on rare pediatric diseases, including by permitting the FDA to take enforcement action against drug sponsors that fail to satisfy pediatric study requirements and by reauthorizing programs that support pediatric research. Specifically, the bill modifies requirements relating to molecularly targeted pediatric cancer investigations to permit research on new drugs in combination with active ingredients that have already been approved, provided certain conditions are met; permits the FDA to take enforcement action against drug sponsors that fail to comply with pediatric study requirements, if such sponsors demonstrated a lack of due diligence in satisfying the requirement; renews the FDA’s authority to award priority review vouchers to sponsors of new products intended to treat rare pediatric diseases through September 30, 2029; and reauthorizes through FY2027 certain funding for the National Institutes of Health to support priority pediatric research. The bill also provides statutory authority for the FDA’s interpretation of the orphan drug exclusivity period. The bill specifies, consistent with FDA regulations, that the seven-year market exclusivity period for drugs for rare diseases or conditions (i.e., orphan drugs) prohibits the approval of the same drug for the same approved use or indication with respect to the disease or condition. (In Catalyst Pharmaceuticals, Inc. v. Becerra , a court rejected the FDA’s interpretation and held that orphan drug exclusivity extends to all uses or indications for the disease or condition.)
